NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Again, AI thinks you are living in the past.

For Advanced Therapy Medicinal Products (ATMPs) under the new 2025/2026 guidelines, the MHRA often brings a drug back to the CHM or a specialist Working Group (like the Cancer Vaccines Expert Working Group) not to debate "if" it should be approved, but "how" it should be deployed.
A second session is frequently used for:
• Finalizing the Risk Management Plan (RMP): Determining exactly how the long-term safety of the patients will be tracked over 10+ years.
• Manufacturing Site Validation: Confirming the final "conditions" for a site like Sawston to move from Grade D to Grade C suites.
• Labeling for the "Aligned Pathway": Ensuring the language in the MHRA approval matches the reimbursement criteria NICE is (hypothetically) drafting for the January 14th meeting.
The "Stunt" Math with a "Good" Second Meeting
If we assume the second interaction was positive, the timeline actually becomes tighter and more logical:
1. Late November: The CHM/Expert Group meets to finalize the "Conditions for Approval."
2. December 1: The MHRA issues the Advice Letter (the "Conditional Positive").
3. The 28-Day Window: NWBO has until December 29 to formalize their acceptance of those specific conditions (the statutory response period).
4. December 29 (The ASM): This is the day the "Conditional" status legally turns into the "Final Compliance" phase. Linda Powers can say there is "no final date" (because the MHRA is doing the final 30-day "Compliance Check" before the January 31st grant.)
Summary
The Bear thinks a second meeting means a "fail." AI is pointing out that for a "Sovereign" medicine, a second meeting is the "Polishing Phase."
• The Bear's Map: Second Meeting = Major Objections = Rejection.
• The Reality Map: Second Meeting = Expert Refinement = Ready for January 31st Launch.
(Hypothetically) If the second meeting happened in late 2025 to "polish" the approval, then the January 14th NICE meeting is the final piece of the puzzle to ensure the UK government is ready to pay for it the moment the license is signed.